What is the recommended treatment for uncomplicated Campylobacter gastroenteritis in otherwise healthy adults?

Treatment for Campylobacter Gastroenteritis

For uncomplicated Campylobacter gastroenteritis in otherwise healthy adults, antibiotic treatment is generally not recommended, as the illness is self-limited; however, treatment with azithromycin or a fluoroquinolone is reasonable for patients with particularly prolonged or severe disease, and should be strongly considered for immunocompromised patients. 1

When to Treat vs. Observe

Most Patients Do NOT Need Antibiotics

• Campylobacter gastroenteritis is self-limited in immunocompetent individuals 1, 2
• While antibiotics reduce symptom duration by approximately 1-2 days, this modest benefit must be weighed against risks 1, 3
• The treatment effect is largest when antibiotics are started early in the illness course 1

Clear Indications for Treatment:

• Immunocompromised patients - even with uncomplicated disease 1
• Severe or prolonged symptoms (>3 days with high fever or significant abdominal pain) 1
• High-risk patients: extremes of age, chronic illness, underlying immunodeficiency 3
• Bacteremia (rare but serious, particularly in immunocompromised hosts) 4

Antibiotic Selection

First-Line Options:

Macrolides (Azithromycin preferred)

• Most strains remain macrolide-susceptible 3
• Effective even when gastrointestinal symptoms have resolved 4
• Historically considered drug of choice 5

Fluoroquinolones (Ciprofloxacin/Levofloxacin)

• Resistance remains low in US/Canadian patients without international travel 1
• However, fluoroquinolone resistance is significantly higher in patients with recent international travel 1
• Effective alternative when macrolides cannot be used 6

Critical Resistance Considerations:

• Approximately 10-15% of C. jejuni isolates show fluoroquinolone resistance in the US 3
• Quinolone resistance may develop during therapy 1
• Geographic variation matters: resistance is much higher in internationally acquired infections 1

Common Pitfalls to Avoid

Do NOT use ceftriaxone - High prevalence of ceftriaxone resistance in C. jejuni makes this ineffective 6

Avoid empiric broad-spectrum therapy for bloody diarrhea - Must rule out STEC (E. coli O157:H7) first, as antibiotics increase hemolytic-uremic syndrome risk 5-10-fold in STEC infections 3

Do NOT treat asymptomatic contacts - No role for empiric or preventive therapy 1

Practical Treatment Algorithm

1. Assess severity and host factors:

   • Immunocompromised? → Treat
   • Severe symptoms (high fever, severe abdominal pain, >3 days duration)? → Treat
   • Otherwise healthy with mild-moderate symptoms? → Supportive care only

2. If treating, choose antibiotic based on travel history:

   • No recent international travel → Azithromycin OR fluoroquinolone
   • Recent international travel → Azithromycin preferred (due to higher fluoroquinolone resistance)

3. Focus on rehydration for all patients regardless of antibiotic decision 7

Important Nuances

The 2017 IDSA guidelines 1 acknowledge that while RCTs demonstrate benefit, the treatment effect is modest and symptoms resolve without intervention. The increasing availability of culture-independent diagnostic tests (CIDT) may facilitate earlier organism identification, potentially making early directed treatment more feasible and beneficial. However, there is no evidence that antimicrobial therapy prolongs the carrier state or encourages relapses, so the risk of treatment is relatively small when indicated 1.